IRIS Archives

Information and Referral and Internet Sightings

IRIS@LISTSERV.ICORS.ORG
Options: Use Forum View

Use Monospaced Font
Show Text Part by Default
Show All Mail Headers

Message: [<< First] [< Prev] [Next >] [Last >>]
Topic: [<< First] [< Prev] [Next >] [Last >>]
Author: [<< First] [< Prev] [Next >] [Last >>]

Print Reply
Subject:
web: Abilify for teens
From:
Sylvia Caras <[log in to unmask]>
Reply To:
[log in to unmask]
Date:
Mon, 11 Jun 2007 10:17:16 -0700
Content-Type:
text/plain
Parts/Attachments:
text/plain (6 lines) 
TheFDA has accepted for priority (six month review target) review the 
sNDA of the atypical antipsychotic Abilify for the treatment of 
pediatric patients (13-17 years old) with schizophrenia.

www.peoplewho.org

ATOM RSS1 RSS2